Literature DB >> 21844878

Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity.

B Gatta-Cherifi1, I Matias, M Vallée, A Tabarin, G Marsicano, P V Piazza, D Cota.   

Abstract

BACKGROUND: The endocannabinoid system is a potential pharmacotherapy target for obesity. However, the role of this system in human food intake regulation is currently unknown.
METHODS: To test whether circulating endocannabinoids might functionally respond to food intake and verify whether these orexigenic signals are deregulated in obesity alongside with anorexigenic ones, we measured plasma anandamide (AEA), 2-arachidonoylglycerol (2-AG) and peptide YY (PYY) changes in response to a meal in 12 normal-weight and 12 non-diabetic, insulin-resistant obese individuals.
RESULTS: Both normal-weight and obese subjects had a significant preprandial AEA peak. Postprandially, AEA levels significantly decreased in normal-weight, whereas no significant changes were observed in obese subjects. Similarly, PYY levels significantly increased in normal-weight subjects only. No meal-related changes were found for 2-AG. Postprandial AEA and PYY changes inversely correlated with waist circumference, and independently explained 20.7 and 21.3% of waist variance. Multiple regression analysis showed that postprandial AEA and PYY changes explained 34% of waist variance, with 8.2% of the variance commonly explained.
CONCLUSION: These findings suggest that AEA might be a physiological meal initiator in humans and furthermore show that postprandially AEA and PYY are concomitantly deregulated in obesity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844878     DOI: 10.1038/ijo.2011.165

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  28 in total

Review 1.  New insights on the role of the endocannabinoid system in the regulation of energy balance.

Authors:  B Gatta-Cherifi; D Cota
Journal:  Int J Obes (Lond)       Date:  2015-09-16       Impact factor: 5.095

2.  Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

Authors:  Erin C Hanlon
Journal:  Psychoneuroendocrinology       Date:  2019-10-04       Impact factor: 4.905

Review 3.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

4.  Short-term aerobic exercise training improves gut peptide regulation in nonalcoholic fatty liver disease.

Authors:  Emily L Kullman; Karen R Kelly; Jacob M Haus; Ciaran E Fealy; Amanda R Scelsi; Mangesh R Pagadala; Chris A Flask; Arthur J McCullough; John P Kirwan
Journal:  J Appl Physiol (1985)       Date:  2016-03-31

5.  Circulating Endocannabinoids and Mortality in Hemodialysis Patients.

Authors:  Hamid Moradi; Christina Park; Elani Streja; Donovan A Argueta; Nicholas V DiPatrizio; Amy S You; Connie M Rhee; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Daniele Piomelli
Journal:  Am J Nephrol       Date:  2020-01-14       Impact factor: 3.754

6.  Nutritional status-dependent endocannabinoid signalling regulates the integration of rat visceral information.

Authors:  Abdessattar Khlaifia; Isabelle Matias; Daniela Cota; Fabien Tell
Journal:  J Physiol       Date:  2017-03-27       Impact factor: 5.182

7.  Endocannabinoids as potential biomarkers: It's all about pre-analytics.

Authors:  Daniel Kratz; Dominique Thomas; Robert Gurke
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-11-10

8.  Determination of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol with Gas Chromatography-Mass Spectrometry: Analytical and Preanalytical Challenges and Pitfalls.

Authors:  Christian Lanz; Johan Mattsson; Felix Stickel; Jean-Francois Dufour; Rudolf Brenneisen
Journal:  Med Cannabis Cannabinoids       Date:  2018-06-12

9.  Circadian Misalignment of the 24-hour Profile of Endocannabinoid 2-Arachidonoylglycerol (2-AG) in Obese Adults.

Authors:  Erin C Hanlon; Rachel Leproult; Kara L Stuhr; Elizabeth M Doncheck; Cecilia J Hillard; Eve Van Cauter
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

10.  Endocannabinoids measurement in human saliva as potential biomarker of obesity.

Authors:  Isabelle Matias; Blandine Gatta-Cherifi; Antoine Tabarin; Samantha Clark; Thierry Leste-Lasserre; Giovanni Marsicano; Pier Vincenzo Piazza; Daniela Cota
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.